| Methods |
2‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= mean DBP 95‐109 mm Hg and mean SBP < 180 mm Hg after run‐in; 16‐week total double‐blind treatment, 4‐week double‐blind treatment at initial fixed dose of losartan monotherapy (week 0‐4), non‐responders titrated to response at weeks 4, 8 or 12 |
| Participants |
Losartan 50 mg: n=188(83 males,105 females); mean age=52.0(10.3) years; n=184: baseline sitting SBP=150.7(11.6) mm Hg, DBP=99.2(3.5) mm Hg, HR=71.5(8.8) bpm;
Placebo: n=181(84 males,97 females); mean age=52.1(11.1) years; n=177: baseline sitting SBP=148.9(11.6) mm Hg, DBP=99.1(3.6) mm Hg, HR=73.1(8.9) bpm |
| Interventions |
Losartan 50 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Adjusted mean change from baseline in trough sitting DBP using mercury sphygmomanometer |
| Notes |
Used week 4 BP data only; BP change and SD of change reported, endpoint BP and SD not reported, baseline SD reported; time of BP measurement not reported; BP data from Figure 1, p. 1152; WDAE reported at endpoint but not at week 4; Jadad score=3; funding source= Pharmacia |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
